|Day Low/High||123.75 / 126.87|
|52 Wk Low/High||127.10 / 223.24|
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ADTN, DOOR, FFKT, FORM, NSH, OBCI, PKX, RGS, SCAI, SPLS, TOL, ZEUS Downgrades: CCE, DTEA, ENT, EVH, ILMN Initiations: FORK Read on to get TheStreet Quant Ratings' detailed report:
Illumina, Inc. (NASDAQ: ILMN) today announced the iHope program, a philanthropic initiative aimed at identifying the genetic causes of undiagnosed rare diseases in children.
Illumina, Inc. (NASDAQ:ILMN) today announced that it will webcast the company's presentation at the Citi Global Healthcare Conference in New York, NY, on December 7, 2016.
The most recent short interest data has been released for the 10/31/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
Illumina, Inc. (NASDAQ: ILMN) today announced it has entered an agreement with Mayo Clinic to make advancements in next-generation sequencing technology with the intent to accelerate Mayo's delivery of genetic and genomic...
Illumina, Inc. (NASDAQ:ILMN) today announced the launch of TruSight® Tumor 170, a 170 gene next-generation sequencing solution to support the transformation of the tumor-profiling paradigm from a series of...
Illumina, Inc. (NASDAQ:ILMN) today announced its full financial results for the third quarter of fiscal year 2016.
The Federal Reserve will again convene in the coming week to discuss monetary policy, but investors will instead focus on what it may mean for a rate hike in December.
Gene sequencer Illumina has shaken investors' faith with negative announcements this year.
Illumina, Inc. (NASDAQ: ILMN) and Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:LH), the world's leading healthcare diagnostics company, today announced that on October 5, 2016, the Düsseldorf...
Khang & Khang LLP (the "Firm") announces that it is investigating claims against Illumina Inc.
Levi & Korsinsky announces it has commenced an investigation of Illumina Inc.
Law Offices of Howard G. Smith announces an investigation on behalf of investors of Illumina Inc.
Illumina, Inc. (NASDAQ: ILMN) announced today that it has contributed over 95,000 human genetic variants to ClinVar, a public database hosted by the National Center for Biotechnology Information (NCBI).
Quest and IBM are rolling out a genomic sequencing service powered by Big Blue's Watson supercomputer.
Do that if you like top ticking crowd favorites, but set a protective stop.
If Twitter puts up a dreadful quarter, shares will sell off again.
We’ll wait until we have more clarity on the issues that plagued the September quarter before considering entry points.
Don't focus on just one day of trading, Jim Cramer says.
Illumina fell 24% on news that it was cutting revenue guidance.
Wall Street sells off as a disappointing quarterly performance from Alcoa heralds a poor start to the third-quarter earnings season and crude oil retreats from highs.
On days like this, the money just keeps sloshing around.
Stock losses accelerate on Tuesday afternoon as a disappointing quarterly performance from Alcoa heralds a poor start to the third-quarter earnings season.
U.S. stocks slipped after a disappointing quarterly performance from Alcoa soured optimism over earnings season.